Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Atrial natriuretic peptide receptor 1 (NPR1), also known as natriuretic peptide receptor A (NPRA) or guanylyl cyclase A (GC-A), is a membrane-bound receptor that primarily binds atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP). These peptides are potent vasoactive hormones crucial for cardiovascular homeostasis, regulating blood pressure, blood volume, and sodium balance. NPR1 functions as a guanylyl cyclase, converting GTP to cGMP upon ligand binding, leading to downstream effects like vasodilation.
Ligand binding to NPR1 activates guanylyl cyclase, increasing cGMP levels, activating PKG, and leading to vasodilation.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Atrial natriuretic peptide receptor 1 (NPR1).